Evidence map›Paper›PMID 33138778›Full record

SynthesisBMC neurology2020

Efficacy and safety of erythropoietin for traumatic brain injury.

Motao Liu, Amy J Wang, Yu Chen, Gexin Zhao, Zhifeng Jiang, Xinbang Wang, Dongliang Shi, Tiansong Zhang, Bomin Sun, Hua He and 2 more

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. P188 Therapy in In Vitro Models of Traumatic Brain Injury.International journal of molecular sciences · 2023
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Motao LiuDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Second Ruijin Street, Shanghai, 200025, China.
Amy J WangDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Yu ChenDepartment of Orthopedic Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Gexin ZhaoState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zhifeng JiangDepartment of Neurosurgery, Ji Zhong Energy Fengfeng Group General hospital, Handan City, 056200, China.
Xinbang WangDepartment of Neurosurgery, The PLA Navy Anqing Hospital, Anqing City, 246000, China.
Dongliang ShiDepartment of Neurosurgery, No.904th Hospital of The People's Liberation Army Joint Logistics Support Force, Wuxi, 214000, China.
Tiansong ZhangDepartment of Traditional Chinese Medicine, Jing-an District Central Hospital, Shanghai, 200437, China.
Bomin SunDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Second Ruijin Street, Shanghai, 200025, China.
Hua HeDepartment of Neurosurgery, Third Affiliated Hospital, Second Military Medical University, Shanghai, 200438, China. hehua1624@smmu.edu.cn.
Ziv WilliamsDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Kejia HuDepartment of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No.197 Second Ruijin Street, Shanghai, 200025, China. dockejiahu@gmail.com.ORCID http://orcid.org/0000-0003-4036-5197
Harvard University · USShanghai Jiao Tong University · CNAnqing City Hospital · CNDongfeng General Hospital · CNJingzhou Central Hospital · CNSecond Military Medical University · CNSun Yat-sen University · CNThe Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

School of Medicine, Shanghai Jiao Tong University GCQN-2019-B10Science and Technology Commission of Shanghai Municipality (CN) 19PJ1407500Shanghai Jiao Tong University YG2019QNA31Shanghai Municipal Health Bureau (CN) 20194Y0067
6 · The paper itself

Abstract

backgroundRecent studies regarding the effects of erythropoietin (EPO) for treating traumatic brain injury (TBI) have been inconsistent. This study conducts a meta-analysis of randomized controlled trials (RCTs) to assess the safety and efficacy of EPO for TBI patients at various follow-up time points.

methodsA literature search was performed using PubMed, Web of Science, MEDLINE, Embase, Google Scholar and the Cochrane Library for RCTs studying EPO in TBI patients published through March 2019. Non-English manuscripts and non-human studies were excluded. The assessed outcomes include mortality, neurological recovery and associated adverse effects. Dichotomous variables are presented as risk ratios (RR) with a 95% confidence interval (CI).

resultsA total of seven RCTs involving 1197 TBI patients (611 treated with EPO, 586 treated with placebo) were included in this study. Compared to the placebo arm, treatment with EPO did not improve acute hospital mortality or short-term mortality. However, there was a significant improvement in mid-term (6 months) follow-up survival rates. EPO administration was not associated with neurological function improvement. Regarding adverse effects, EPO treatment did not increase the incidence of thromboembolic events or other associated adverse events.

conclusionsThis meta-analysis indicates a slight mortality benefit for TBI patients treated with EPO at mid-term follow-up. EPO does not improve in-hospital mortality, nor does it increase adverse events including thrombotic, cardiovascular and other associated complications. Our analysis did not demonstrate a significant beneficial effect of EPO intervention on the recovery of neurological function. Future RCTs are required to further characterize the use of EPO in TBI.

Indexed as

AdultBrain Injuries, TraumaticErythropoietinHumansOutcome Assessment, Health CareRandomized Controlled Trials as TopicErythropoietinAdverse eventsErythropoietinMeta-analysisMortalityNeurological function improvementTraumatic brain injury

Identifiers

PMID33138778
PMCPMC7604969
OpenAlexW3095470093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.